Novavax, Inc. (NVAX) P/E Ratio History
Premium ValuationTrading at 3.7x vs 5Y avg 3.2x · 75th percentile · Premium to historical baseline · Data 2025–2025
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, Novavax, Inc. (NVAX) trades at a price-to-earnings ratio of 3.7x, with a stock price of $9.46 and trailing twelve-month earnings per share of $-0.54.
The current P/E is 15% above its 5-year average of 3.2x. Over the past five years, NVAX's P/E has ranged from a low of 2.4x to a high of 4.9x, placing the current valuation at the 75th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, NVAX trades at a 84% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
Relative to the broader market, NVAX trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NVAX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NVAX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
NVAX P/E vs Peers
Vaccines and Infectious Disease peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $137B | 17.7 | - | -4% | |
| $103B | 11.8 | - | +46% | |
| $107B | 7.2Lowest | 0.50Best | +348% | |
| $2B | 77.5 | - | +503%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
NVAX Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Dec 31 2025 | $6.72 | $2.39 | 2.8x | -13% |
| FY2025 Q3 | - | $8.67 | $1.77 | 4.9x | +52% |
| FY2025 Q2 | Jun 30 2025 | $6.30 | $2.26 | 2.8x | -14% |
| FY2025 Q1 | Mar 31 2025 | $6.41 | $2.65 | 2.4x | -25% |
Average P/E for displayed period: 3.2x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
1+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NVAX — Frequently Asked Questions
Quick answers to the most common questions about buying NVAX stock.
What is NVAX's P/E ratio?
Novavax, Inc. (NVAX) trailing twelve-month P/E ratio is 3.7x, based on TTM diluted EPS of $-0.54. The 5-year average P/E is 3.2x and the historical range spans 2.4x to 4.9x.
Is NVAX stock overvalued or undervalued?
NVAX trades at 3.7x P/E, near its 5-year average of 3.2x. The 75th percentile ranking within the 2.4x–4.9x historical range places valuation within normal bounds.
Is NVAX stock expensive?
NVAX is fairly valued relative to its own history. The current P/E of 3.7x is near the 5-year average of 3.2x (75th percentile of historical range).
What is NVAX's historical P/E range?
Over the past 5 years, NVAX's P/E ratio has ranged from 2.4x to 4.9x, with a median of 2.8x and an average of 3.2x. The current P/E of 3.7x places the stock at the 75th percentile of this range. Full historical data spans 2025–2025.
How does NVAX's P/E compare to the S&P 500?
NVAX trades at 3.7x P/E versus the S&P 500 median of 25.9x. The 86% discount to the market suggests lower growth expectations or perceived higher risk.
How does NVAX's valuation compare to Healthcare peers?
Novavax, Inc. P/E of 3.7x compares to the Healthcare sector median of 23.4x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is NVAX's PEG ratio?
NVAX PEG ratio is N/A, based on a P/E of 3.7x and EPS growth of 306.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is NVAX's earnings yield?
NVAX earnings yield is 26.85%, the inverse of its 3.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.